A Phase 3 interventional study of Rotigotine in Early-Stage Parkinson's Disease, sponsored by UCB Pharma. Completed at 42 sites in 2 countries. Open to participants aged 31 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 13th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2002, is one of 20 in phase 3, and was the 16th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 31 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 3 started in 2002.
This study's enrollment of 217 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2002, is one of 19 in phase 3, and was the 17th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
This is the open-label extension to the randomized, double-blind, placebo-controlled SP512 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rotigotine
Drug: Rotigotine
Rotigotine trans-dermal patches: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours. After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.
Also known as: Neupro
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: 7 years
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: 7 years
Mean Epworth Sleepiness Scale Score During the Open-label Extension.
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.
Time frame: Visit 9 (end of year 1), Visit 13 (end of year 2), Visit 17 (end of year 3), Visit 21(end of year 4), Visit 25 (end of year 5), Visit 29 (end of year 6), End of Treatment (last study visit or early withdrawal visit)
An Open-Label Extension to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects with Early-Stage Idiopathic Parkinson's Disease from June 2002 to November 2008
| Milestone | Rotigotine |
|---|---|
| Started | 217 |
| Completed | 0 |
| Not completed | 217 |
| Withdrew: Major protocol violation | 1 |
| Withdrew: Lack of efficacy | 12 |
| Withdrew: Adverse event | 52 |
| Withdrew: Unsatisfactory compliance of subject | 6 |
| Withdrew: Subject withdrew consent | 27 |
| Withdrew: Study ended per sponsor | 102 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Other: pi discretion | 5 |
| Withdrew: Other: subject moving | 3 |
| Withdrew: Other: brain surgery controlled symptoms | 1 |
| Withdrew: Other: house bound; can't get to clinic | 1 |
| Withdrew: Other: subject enrolled in other trial | 1 |
| Withdrew: Other: site terminated participation | 2 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| Subjects | Rotigotine |
|---|---|
| Number of Subjects With at Least One Adverse Event During This Open-label Extension Study | 214 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| subjects | Rotigotine |
|---|---|
| Number of Subjects Who Withdrew From the Trial Due to an Adverse Event. | 52 |
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.
| Score on a scale | Rotigotine |
|---|---|
| Visit 9 (end of year 1) (n=209) | 7.3 ± 4.4 |
| Visit 13 (end of year 2) (n=209) | 7.9 ± 4.9 |
| Visit 17 (end of year 3) (n=209) | 8.2 ± 5.2 |
| Visit 21 (end of year 4) (n=209) | 8.4 ± 5.0 |
| Visit 25 (end of year 5) (n=209) | 8.8 ± 5.0 |
| Visit 29 (end of year 6) (n=209) | 8.5 ± 5.0 |
| End of Treatment (n=216) | 9.0 ± 5.4 |
Collected over Up to 7 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 102/216 (47.2%) | 206/216 (95.4%) |
| Event | Rotigotine |
|---|---|
| Myocardial infarctionCardiac disorders | 6/216 |
| Chest painGeneral disorders | 6/216 |
| PneumoniaInfections and infestations | 5/216 |
| Hip fractureInjury, poisoning and procedural complications | 5/216 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/216 |
| Parkinson's diseaseNervous system disorders | 5/216 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 4/216 |
| SyncopeNervous system disorders | 4/216 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/216 |
| Coronary artery diseaseCardiac disorders | 3/216 |
| Event | Rotigotine |
|---|---|
| SomnolenceNervous system disorders | 116/216 |
| Oedema peripheralGeneral disorders | 79/216 |
| FallInjury, poisoning and procedural complications | 69/216 |
| NauseaGastrointestinal disorders | 66/216 |
| DizzinessNervous system disorders | 58/216 |
| Back painMusculoskeletal and connective tissue disorders | 53/216 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 51/216 |
| InsomniaPsychiatric disorders | 47/216 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 40/216 |
| DepressionPsychiatric disorders | 38/216 |
| Age, Categorical(Participants) | Rotigotine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 119 |
| >=65 years | 97 |
| Age, Continuous(years) | Rotigotine |
|---|---|
| Mean | 63.2 ± 10.3 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 69 |
| Male | 147 |
| Region of Enrollment(participants) | Rotigotine |
|---|---|
| United States | 186 |
| Canada | 30 |
The record gives a start of Jun 2002, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine